S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda

Progyny (PGNY) Stock Price, News & Analysis

$32.70
+0.82 (+2.57%)
(As of 04/19/2024 ET)
Today's Range
$31.88
$32.76
50-Day Range
$31.88
$41.62
52-Week Range
$29.44
$44.95
Volume
1.13 million shs
Average Volume
653,283 shs
Market Capitalization
$3.14 billion
P/E Ratio
52.74
Dividend Yield
N/A
Price Target
$48.30

Progyny MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
47.7% Upside
$48.30 Price Target
Short Interest
Bearish
7.87% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.33mentions of Progyny in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$4.57 M Sold Last Quarter
Proj. Earnings Growth
38.57%
From $0.70 to $0.97 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.35 out of 5 stars

Medical Sector

115th out of 907 stocks

Miscellaneous Health & Allied Services, Not Elsewhere Classified Industry

1st out of 5 stocks

PGNY stock logo

About Progyny Stock (NASDAQ:PGNY)

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

PGNY Stock Price History

PGNY Stock News Headlines

“More countries ditch the US dollar”
Since March 2018, China started purchasing oil in gold-backed yuan. By December 2022, Foreign Minister Wang Yi stated that Chinese-Arab relations experienced a "historic improvement." after arab nations ditched the dollar to trade with China. On June 6, 2023 China told its banks to slash interest rates on US dollars.
Progyny, Inc. (PGNY)
Progyny (NASDAQ:PGNY) Rating Reiterated by Truist Financial
“More countries ditch the US dollar”
Since March 2018, China started purchasing oil in gold-backed yuan. By December 2022, Foreign Minister Wang Yi stated that Chinese-Arab relations experienced a "historic improvement." after arab nations ditched the dollar to trade with China. On June 6, 2023 China told its banks to slash interest rates on US dollars.
Progyny CFO sells over $419k in company stock
PGNY Apr 2024 20.000 call
PGNY Apr 2024 55.000 call
PGNY Apr 2024 30.000 call
PGNY Apr 2024 40.000 put
Truist Financial Reaffirms Their Buy Rating on Progyny (PGNY)
See More Headlines
Receive PGNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Progyny and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
4/21/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Miscellaneous health & allied services, not elsewhere classified
Sub-Industry
N/A
Current Symbol
NASDAQ:PGNY
Fax
N/A
Employees
563
Year Founded
2008

Price Target and Rating

Average Stock Price Target
$48.30
High Stock Price Target
$57.00
Low Stock Price Target
$43.00
Potential Upside/Downside
+47.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Net Income
$62.04 million
Pretax Margin
6.49%

Debt

Sales & Book Value

Annual Sales
$1.09 billion
Cash Flow
$0.67 per share
Book Value
$5.77 per share

Miscellaneous

Free Float
82,366,000
Market Cap
$3.14 billion
Optionable
Optionable
Beta
1.48

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

PGNY Stock Analysis - Frequently Asked Questions

Should I buy or sell Progyny stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Progyny in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PGNY shares.
View PGNY analyst ratings
or view top-rated stocks.

What is Progyny's stock price target for 2024?

10 equities research analysts have issued 1 year price targets for Progyny's shares. Their PGNY share price targets range from $43.00 to $57.00. On average, they predict the company's share price to reach $48.30 in the next year. This suggests a possible upside of 47.7% from the stock's current price.
View analysts price targets for PGNY
or view top-rated stocks among Wall Street analysts.

How have PGNY shares performed in 2024?

Progyny's stock was trading at $37.18 at the beginning of the year. Since then, PGNY shares have decreased by 12.0% and is now trading at $32.70.
View the best growth stocks for 2024 here
.

When is Progyny's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our PGNY earnings forecast
.

How were Progyny's earnings last quarter?

Progyny, Inc. (NASDAQ:PGNY) issued its quarterly earnings data on Tuesday, February, 27th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.09 by $0.04. The company earned $269.94 million during the quarter, compared to the consensus estimate of $274.08 million. Progyny had a net margin of 5.70% and a trailing twelve-month return on equity of 12.64%. Progyny's quarterly revenue was up 26.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.03 earnings per share.

What guidance has Progyny issued on next quarter's earnings?

Progyny issued an update on its first quarter 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of 0.330-0.350 for the period, compared to the consensus earnings per share estimate of 0.180. The company issued revenue guidance of $285.0 million-$292.0 million, compared to the consensus revenue estimate of $314.0 million.

What is David Schlanger's approval rating as Progyny's CEO?

25 employees have rated Progyny Chief Executive Officer David Schlanger on Glassdoor.com. David Schlanger has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Progyny own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Progyny investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Marvell Technology (MRVL), Alteryx (AYX), Micron Technology (MU), AbbVie (ABBV), Home Depot (HD), Advanced Micro Devices (AMD).

When did Progyny IPO?

Progyny (PGNY) raised $150 million in an initial public offering on Friday, October 25th 2019. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Citigroup, Piper Jaffray, SVB Leerink and TPG Capital were co-managers.

Who are Progyny's major shareholders?

Progyny's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Congress Asset Management Co. MA (1.05%), Deepwater Asset Management LLC (0.41%), International Assets Investment Management LLC (0.16%), Congress Wealth Management LLC DE (0.16%), Los Angeles Capital Management LLC (0.05%) and Radnor Capital Management LLC (0.04%). Insiders that own company stock include Cheryl Scott, David J Schlanger, Group Holdings (Sbs) Advis Tpg, Jennifer Bealer, Kevin K Gordon, Mark S Livingston, Michael E Sturmer, Norman Payson, Peter Anevski, Robert Michael Floyd and Tpg Gp A, Llc.
View institutional ownership trends
.

How do I buy shares of Progyny?

Shares of PGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PGNY) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners